Related Experiment Video
Updated: Apr 21, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Renal denervation in the treatment of resistant arterial hypertension
Thomas Lambert1, Wilhelm Schützenberger, Clemens Steinwender
11st Medical Department of Cardiology, Linz General Hospital, Johannes Kepler University School of Medicine, Krankenhausstraße 9, 4020, Linz, Austria, thomas.lambert@akh.linz.at.
Abstract:
Patients with resistant arterial hypertension have an increased risk of stroke, myocardial infarction, heart failure, and chronic kidney disease. In many cases, limitations of pharmacological treatment like intolerance and adherence to the antihypertensive medications are present in the clinical setting. In this context, new treatment options like trans-femoral sympathetic renal nerve denervation is, even after publication of the Symplicity HTN-3 trial, a promising new treatment option.
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Vasodilators
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

